GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.

Jigsaw_Pieces
GSK's Trelegy is a triple combination approved for asthma by FDA • Source: Shutterstock

GlaxoSmithKline plc's inhaler Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanteral) is the first closed triple combination approved for asthma in the US, opening the door to an expanded commercial opportunity for the brand. Trelegy has already been approved for chronic obstructive pulmonary disease in the US and Europe and is one of the company's key growth drivers in respiratory disease.

The company announced the US Food and Drug Administration approval of Trelegy for patients 18 and older on 9 September....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Respiratory

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.